Short-acting GHRH analogue studied in GH pulsation research.
Guidance only. Confirm dosing with your prescribing clinician.
Complete a quick screening to proceed
CJC-1295 No DAC is studied for its ability to stimulate natural growth hormone release in pulsatile patterns.
This peptide is delivered using Zenith's Dual Chamber Precision Pen, allowing automatic peptide reconstitution and accurate dosing without manual mixing.
This peptide compound has been identified and characterised in scientific research literature.
In biological research contexts, it has been studied for its involvement in specific cellular and physiological pathways.
This compound continues to be examined in laboratory and clinical research environments.
Research literature describes interactions with specific receptor systems and signalling pathways.
Ongoing studies investigate its potential applications in controlled research environments.
CJC-1295 No DAC has been referenced in research relating to:
This compound is primarily available in research and specialised formulation contexts.
Injectable formats may not be approved therapeutic medicines in Australia.
Information provided is for educational and research awareness purposes only.
CJC-1295 No DAC injectable formulations are not listed on the Australian Register of Therapeutic Goods (ARTG).
Topical cosmetic products containing this compound may be available under cosmetic regulatory frameworks.
Always consult a qualified medical professional regarding prescription medicines.
Formulated based on published research frameworks
Third-party tested for purity and potency
Clinical-grade compounding in TGA-regulated facilities
This product is a general wellness formulation. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before use. All formulations are compounded in Australian TGA-regulated facilities.
Complete screening to purchase
